Astellas Pharma (United States)

Astellas Pharma is a Japanese multinational pharmaceutical company with significant US operations. The company focuses on urology, oncology, transplant, and infectious disease therapies. Key products include XTANDI (enzalutamide) for prostate cancer, Prograf (tacrolimus) for transplant rejection prevention, Myrbetriq (mirabegron) for overactive bladder, and VESIcare (solifenacin) for urinary incontinence. Astellas combines innovative science with patient-focused healthcare solutions.